Aptar

Aptar Pharma announces its Unidose Powder Nasal Spray System is used in ENA Respiratory’s Phase 2 clinical study of INNA 051, an investigational nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections. ow.ly/knwo50YwqEW

Today, on Global Recycling Day, we are reminded how recycling can reduce waste. At #AptarPharma, we integrate recyclability & material efficiency into developing #drugdelivery & dispensing solutions where regulations & patient safety allow. #sustainability

We are pleased to announce that Gael Touya, has been appointed President and Chief Executive Officer of Aptar effective September 1, 2026. He succeeds Stephan B. Tanda, who will retire after nearly a decade as President and CEO. Learn more: ow.ly/u38A50YvAvw

Aptar Pharma announces its proprietary #nasaldelivery system is being utilized in LTR Pharma Limited’s Phase II clinical study of SPONTAN®, an investigational intranasal spray under development for the treatment of erectile dysfunction. ow.ly/87PP50Yv0NG #AptarPharma

At #PDAWeek, meet #AptarPharma & #GatewayAnalytical at Booth 204. From high-quality #injectabledrugdelivery solutions to particulate analysis & CCI testing, connect with our experts to learn how we help ensure parenteral product performance, quality & #regulatorycompliance.

Proud to share that #AptarPharma has received a #Haleon Supplier Innovation Award 2026, recognizing our close collaboration with Haleon on nasal spray innovation for Otrivin and Theraflu. #SupplierInnovation #WinningTogether

Aptar Pharma announces a technical collaboration with COVIRIX Medical to assess feasibility of adapting our proprietary dry powder inhaler (DPI) platform for delivery of an antiviral compound targeting pandemic‑potential respiratory viruses. ow.ly/4OgZ50YsZiv

We’re proud to share that #AptarPharma’s stand at Pharmapack 2026 has been awarded #BetterStands Gold certification - achieving a zero waste stand by utilizing reusable & recyclable components. Thanks to all involved in making this possible!

Glaucoma often has no early symptoms, which makes early detection essential. This #WorldGlaucomaWeek, taking place March 8-14, 2026, join Aptar Pharma in our support of global efforts to raise awareness and protect vision. #Glaucoma #EyeCare

Proud to announce that P&G has named our #AptarPharma Consumer Healthcare division in Europe one of its 2025 External Business Partner #ExcellenceAward recipients. Thank you to our teams for their continued dedication, and to P&G for this honor.

Aptar Reports Fourth Quarter and Annual 2025 Results ow.ly/UxZB50Y9EqG

Some highlights of of Aptar Pharma’s presence at Pharmapack 2026 in Paris last month. A big thank you to everyone who stopped by our booth and joined our expert talks. We look forward to connecting with you again soon! #AptarPharma #DrugDelivery #Pharmapack2026

Several #AptarPharma experts spoke on a wide variety of topics at #Pharmapack2026! Great turnout at our Learning Labs discussing sterile packaging & patient‑centric nasal delivery, at roundtables on connected devices & sustainability & the product gallery on next‑gen innovation.

At last night's #Pharmapack2026 Awards Aptar Pharma was proud to be finalists in two categories - Patient Centric & Delivery & Device. Congrats to all the winners! Stop by Booth 4C28 today to learn more about our latest innovations! We'd love to see you! #AptarPharma #Innovation

Day 2 of Pharmapack! At Booth 4C28, Aptar Pharma is showcasing our EcoVadis Platinum sustainability leadership & innovations including Zen30 Futurity™, APF Futurity™ and Micro+ Futurity™. Visit us today to find out more! #AptarPharma #Innovation #Sustainability

We’re proud to share that Aptar has once again been named to the CDP Climate Change A List, placing us among the top 4% of the nearly 20,000 companies scored by CDP that are taking bold, measurable action on climate stewardship. Learn more: ow.ly/FwVQ50Y0WZy

Great first day at Pharmapack! Join us tomorrow for two great sessions: 🔹 Christophe Marie on Eco‑Design Packaging Playbook 12:40–13:25 | Conference 4B72 🔹 Jonathan Mulpas presenting the Orbital™ DPI (Dry Powder Inhaler) 14:30 | Product Gallery & Start-Up Pitches. #AptarPharma

It’s Day 1 of #Pharmapack2026! Discover how #AptarPharma is unlocking new potential in #drugdelivery! Be sure to visit us at Booth 4C28 to see our Bidose System (BDS) delivering CARDAMYST™, Orbital™ DPI, Zen30 Futurity™ & our Unidose (UDS) delivering Enbumyst™. See you there!

Pleased to share that Aptar’s Christophe Marie will join a high‑level panel discussion this week at #Pharmapack2026 on eco‑design insights from cosmetics & pharma. Join us on Thursday, January 22 at 12:40, Conference 4B72 to learn about driving sustainable packaging forward!

Congrats to Haleon on winning the WorldStar Awards 2026 for Theraflu Nasal Mist, featuring #AptarPharma’s proprietary Lateral Control System (LCS) technology, helping make nasal administration more intuitive & accessible for more people. #WorldStarAwards #Packaging #Awards